Proprietary Product Update

BioProgress PLC
31 May 2007


For Immediate Release                                                31 May 2007


                                BioProgress PLC

                     Proprietary Product Development Update


London, UK, 31 May 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM:
BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company, today
announces an update on its product development program.


BioProgress has nine integrated enabling drug delivery technologies with
pharmaceutical and healthcare applications. The Company has in development over
30 patent protected products using these core enabling technologies. The
developments are classed into three main categories

1.       OTC and Nutritional Products

2.       Line extensions for acquired Pharmaceutical Brands

3.       Innovative Products suitable for out-licensing or for sale by Dexo
         BioPharm



1. OTC and Nutritional Products

The Company has launched a range of Soluleaves(TM) nutritional products in the
United States and Europe. In addition, in the OTC pharmaceutical sector, the
Company has developed a range of Soluleaves(TM) products for launch initially
through Dexo US. The products include respiratory drugs, cough / cold and sore
throat products. These products do not require pre-FDA approval and will be
marketed throughout 2007. Development work is carried out at the Company's
facilities in Cambridge, UK and in Tampa, USA. The range includes the following:


                                        Technology             Development Phase

DBP130       Anti-Diarrhoea             Soluleaves(TM)         Pre-registration
DBP147       Local Anaesthetic          Soluleaves(TM)         Launch phase - US
DBP211       Decongestant               Soluleaves(TM)         Pre-registration
DBP214       Anti-histamine             Soluleaves(TM)         Pre-registration
DBP216       Analgesic                  TabWrap(TM)            Scale Up
DBP310       Analgesic - basic          FastWrap               Pre-registration
DBP312       Analgesic - combination    FastWrap               Pre-registration
DBP314       Analgesic - Cold & flu     FastWrap               Pre-registration


The Global OTC market for analgesics and cough/cold products is worth $16.7
Billion per annum. Similar new novel patented pharmaceutical technologies can
achieve sales penetration rates of approximately one percent of the relevant
market share.


2. Line Extensions for acquired Pharmaceutical Brands

BioProgress has acquired a number of branded medicines suitable for immediate
extension utilizing one of the Company's enabling systems. The main developments
in this area are:

                                         Product              Territory   Launch

DBP213     Cough                         Ah-Chew extension    USA         2007
DBP215     Cough & Cold                  Ah-Chew extension    USA         2007
DBP272     Gastric Reflux -Combo         RocGe                EU          2008
DBP274     Gastric Reflux - Basic        RocGel               Global      2008/9
DBP276     Gastric Reflux - Chewable     RocGel               Global      2008/9


The Ah-Chew line extensions use Soluleaves(TM) technology and will be the first
oral thin film within the US DESI prescription market. The line extensions for
RocGel use the liquid SoluPol technology, as well as a chewable tablet,  and are
expected to be a core driver for pan-European sales within the gastro-intestinal
market. The SoluPol range of products has been developed by the Cambridge
Development team.


3. Key Innovative Developments

The Company's core new development includes the following:-

DBP117 - Anti-Migraine

The Development team has been able to overcome significant technical challenges
to place an anti-migraine drug of a class of compound known as a triptan into an
oral film strip. The triptan market includes brands such as Imitrex(TM) (GSK)
and Zomig(TM) (AstraZeneca) and is worth $3.1 billion in 2007 (Datamonitor)
growing at 3.1% per annum. A number of these products are converting from
Prescription to Over the Counter use which is expected to expand the market.


The product has passed the initial formulation phase and is due to commence
scale-up manufacturing trials in H2 2007. The product is planned for submission
to US and EU regulatory authorities during 2008. It is expected that DBP117 will
achieve peak sales revenues of 1 to 1.5 percent of the Global triptan market
share per annum.


DBP118 - Anti-emesis

BioProgress has developed a product for anti-emesis which has been induced by
cancer therapy. The category of medicines is called 5-HT3 antagonists, such as
Zofran(TM) (GSK) and Kytril(TM) (Roche),  have become the mainstay of the
treatment of oncology induced nausea.


The Company has formulated a DBP118 using the Oradisc(TM) technology, owned by
Uluru Inc. The product uses a buccal disc that can dissolve gradually over time,
allowing for the sustained release of the active drug.


It is expected that the product will enter into pharmacokinetic studies during
2008 with the product being filed using the NDA 505 (b) (2) regulatory pathway.
The Company is expecting peak sales revenues to be in the region of $32-40m per
annum.


DBP121 - Smoking Cessation Product

BioProgress has developed a new concept in smoking cessation. Whilst lozenges
and microtabs take 10-30 minutes to deliver their nicotine content, a cigarette
typically will deliver the effects of its nicotine in seconds. Current therapies
do not mimic this "high" and therefore smokers find it difficult to reduce the
number of cigarettes accordingly. The current global smoking cessation market is
estimated to be $2.3 billion (Datamonitor)


The Company completed its first volunteer study in April 2007 as an open
assessment study in volunteer smokers. This study showed a marked decrease in
cravings using DBP121. Along with positive taste and consumer acceptability
information, this data has been instrumental in the Company's discussions with
several global partners. BioProgress is currently assessing all of the potential
partners from global to regional partners in order to extract the maximum
benefit for the Company.


From detailed market analyses and from other launches of new nicotine
replacement dosage forms, BioProgress anticipates that DBP121has a peak sales
potential of $150 to 200m per annum within the smoking cessation market.


DBP167 - Analgesic

DBP167 is a series of developments using a novel form of ibuprofen in
conjunction with polymer technology. The development is focusing on the
requirement to deliver analgesia significantly quicker into the blood stream
than traditional pharmaceutical tablets. Published data shows that standard
paracetamol type of analgesics can take 40-90 minutes before the patient is able
to see a noticeable reduction in pain. BioProgress's product has demonstrated
impact in only a few minutes, anything from a simple headache, migraine or
breakthrough pain can be effectively and quickly treated.


SoluPol liquids, Meltums (melt in the mouth), NRobe(TM) and FastWrap versions
are all scheduled for development as analgesic indications along with a novel
sachet formulation integrating decongestants for line extensions into the Ah-
Chew franchise.


The global OTC market for analgesics alone is currently $6.2 billion with the
cough-cold market being $10.5 billion. With the addition of the prescription
analgesic market, BioProgress believes that it has a unique marketing advantage
over the main competitors. The products will be promoted into the prescription
market as well as the OTC market and will become a cornerstone of the
BioProgress core product developments.


DBP167 will enter regulatory submission in H2 2007, with the further
developments progressing through formulation and scale-up.


With the target OTC market being in excess of $16 billion, the company estimates
that its innovative prescription and OTC strategy would lead to a 1 - 1.5 %
market share of the major pharmaceutical markets.


Steve Martin, Chief Development Officer said:

"BioProgress has made significant progress over the last year converting its
enabling technologies into tangible product developments that meet consumer and
partner expectations. We have launched three new technologies, EntWrap, FastWrap
and Meltums. Each of these technologies has been well received by potential
partners and as the Company has progressed in its developments, the data
accumulated has been instrumental in increasing the partner interest.


The Development team is working on a number of confidential product projects
with other pharmaceutical companies using the full range of enabling
technologies. With revenues currently being received from its restructured NRobe
technology licence agreement, the Company is in a strong position to deliver
its own technologies to the consumer market.


Product launches are scheduled throughout 2007 and beyond, a healthy pipeline is
essential for the future growth and profitability of BioProgress. The
Development Team has worked tirelessly to create our vision of medicines that
act quickly and are easy to take."


For further information:

BioProgress Plc                                            + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications                                    + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGELpolymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to www.bioprogress.com


Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAURVURBBRVOUR